{"id":"single-group-open-label","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108795","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insufficient information provided to characterize the molecular mechanism of action. The submission includes only study design (single group, open-label), company affiliation (Daewoong Pharmaceutical Co. LTD.), and phase (marketed), but lacks the drug name, brand name, or molecular target necessary to establish mechanism.","oneSentence":"Unable to determine specific mechanism without drug name or identifier.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:08:16.029Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07450833","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers","status":"COMPLETED","sponsor":"Benfovir AG","startDate":"2022-03-01","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT07347808","phase":"PHASE1","title":"A Pharmacokinetic Study of VCT220 With Moderate Renal Impairment Patients","status":"COMPLETED","sponsor":"Vincentage Pharma Co., Ltd","startDate":"2025-12-25","conditions":"Obesity & Overweight","enrollment":16},{"nctId":"NCT06617182","phase":"PHASE2","title":"Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury.","status":"RECRUITING","sponsor":"Yongquan Shi","startDate":"2024-09-30","conditions":"Radiation Enteritis","enrollment":150},{"nctId":"NCT06412666","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).","status":"RECRUITING","sponsor":"Cytokinetics","startDate":"2024-05-29","conditions":"Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy","enrollment":55},{"nctId":"NCT07039357","phase":"NA","title":"Reconfirming the Safety and Performance of the Glyconics-DS System in Known Populations With and Without Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Glyconics Ltd","startDate":"2026-01-28","conditions":"Diabetes Mellitus, Healthy","enrollment":100},{"nctId":"NCT07495969","phase":"NA","title":"Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR）","status":"NOT_YET_RECRUITING","sponsor":"Feng Gao","startDate":"2026-04-01","conditions":"Symptomatic Non-acute Intracranial Artery Occlusion, Ischemic Stroke","enrollment":286},{"nctId":"NCT07498387","phase":"NA","title":"Management of Catatonic Features in Adolescents With Profound Autism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tanta University","startDate":"2026-01-01","conditions":"Autism Spectrum Disorder, Catatonia","enrollment":30},{"nctId":"NCT06739122","phase":"PHASE3","title":"A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-01-10","conditions":"Type 2 Diabetes","enrollment":55},{"nctId":"NCT06431932","phase":"PHASE1, PHASE2","title":"Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity","status":"RECRUITING","sponsor":"Ove Andersen","startDate":"2026-03-24","conditions":"Multimorbidity, Healthy","enrollment":60},{"nctId":"NCT06149559","phase":"PHASE2, PHASE3","title":"A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2024-06-14","conditions":"Generalized Myasthenia Gravis","enrollment":12},{"nctId":"NCT07246564","phase":"PHASE4","title":"Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2025-12-01","conditions":"Myasthenia Gravis","enrollment":40},{"nctId":"NCT07493135","phase":"PHASE1, PHASE2","title":"A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Immunofoco Biotechnology Co., Ltd","startDate":"2026-03-31","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":30},{"nctId":"NCT07493317","phase":"PHASE2","title":"Neutralizing Interleukin (IL)-6","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-03","conditions":"Major Depressive Disorder","enrollment":60},{"nctId":"NCT06468826","phase":"PHASE1","title":"A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)","status":"COMPLETED","sponsor":"Amgen","startDate":"2024-06-18","conditions":"End-Stage Renal Disease (ESRD)","enrollment":13},{"nctId":"NCT07178366","phase":"NA","title":"Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-05-10","conditions":"Acute-on-Chronic Liver Failure (ACLF)","enrollment":56},{"nctId":"NCT07250048","phase":"PHASE1","title":"A Study in Healthy Men to Find Out How Different Doses of BI 3009947 Are Tolerated and How Different Formulations or Food Influence How BI 3009947 is Taken up Into the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2025-11-21","conditions":"Healthy","enrollment":40},{"nctId":"NCT07493148","phase":"PHASE2","title":"Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL","status":"RECRUITING","sponsor":"Ou Bai, MD/PHD","startDate":"2026-04-30","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":50},{"nctId":"NCT06538623","phase":"PHASE2","title":"Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2024-08-23","conditions":"Pancreatic Neoplasms, Neoplasm Metastasis, Hepatic Metastasis of Pancreatic Cancer","enrollment":40},{"nctId":"NCT07488273","phase":"NA","title":"Whey Protein Supplementation and Serum Mineral Status in Elite Endurance and Power Athletes","status":"COMPLETED","sponsor":"Monira Aldhahi","startDate":"2026-02-25","conditions":"Athletic Performance","enrollment":59},{"nctId":"NCT07490457","phase":"NA","title":"Intraoperative Ketamine for Chronic Postoperative Pain After Open-Heart Surgery","status":"NOT_YET_RECRUITING","sponsor":"Bursa City Hospital","startDate":"2026-04-15","conditions":"Cardiac Anaesthesia, Chronic Pain, Post Operative Pain, Chronic","enrollment":100},{"nctId":"NCT07490808","phase":"NA","title":"Peri-procedural Hydration to Prevent Acute Kidney Injury After Pulsed Field Ablation for Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2026-03","conditions":"Atrial Fibrillation (AF), Acute Kidney Injury","enrollment":290},{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT07491783","phase":"PHASE2","title":"Nano-Carbon Iron Suspension Injection Combined With Radiotherapy for Solid Tumors Phase II Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Enray Pharmaceutical Sciences Company","startDate":"2026-03-27","conditions":"HNSCC, Soft Tissue Cancer","enrollment":52},{"nctId":"NCT07490210","phase":"PHASE2","title":"Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-05-01","conditions":"Oligometastatic Prostate Cancer","enrollment":300},{"nctId":"NCT07354074","phase":"PHASE2","title":"Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-05-04","conditions":"Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive","enrollment":50},{"nctId":"NCT06983665","phase":"NA","title":"Human Bioequivalence Study of Liposomal Amphotericin B for Injection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","startDate":"2025-05-25","conditions":"Invasive Fungal Infections, Neutropenic Fever, Visceral Leishmaniasis","enrollment":42},{"nctId":"NCT06916078","phase":"PHASE1","title":"A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-04-23","conditions":"Liver Dysfunction, Healthy","enrollment":33},{"nctId":"NCT04534556","phase":"NA","title":"Wireless Nerve Stimulation Device To Enhance Recovery After Stroke","status":"RECRUITING","sponsor":"Baylor Research Institute","startDate":"2021-09-01","conditions":"Stroke, Chronic Stroke, Upper Extremity Paresis","enrollment":42},{"nctId":"NCT06585891","phase":"PHASE1","title":"Study of a Human Bispecific Antibody VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-10-07","conditions":"HIV Infection","enrollment":24},{"nctId":"NCT05626114","phase":"PHASE2","title":"A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2023-03-23","conditions":"Geographic Atrophy","enrollment":60},{"nctId":"NCT07199465","phase":"PHASE1","title":"A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-04-24","conditions":"Cytomegalovirus Prophylaxis","enrollment":40},{"nctId":"NCT07488247","phase":"PHASE2","title":"Phase IIb and III Safety and Efficacy Study Chlorin E6 Gel Photodynamic Therapy for Diabetic Foot Ulcers:","status":"COMPLETED","sponsor":"United Medical and Dental College","startDate":"2025-06-20","conditions":"Diabetic Foot Ulcer (DFU)","enrollment":30},{"nctId":"NCT05658003","phase":"PHASE2","title":"A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-05-05","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":63},{"nctId":"NCT06388564","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2024-10-11","conditions":"Chronic Graft-versus-host-disease","enrollment":120},{"nctId":"NCT07006792","phase":"PHASE4","title":"A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-06-16","conditions":"Atopic Dermatitis","enrollment":200},{"nctId":"NCT06311682","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis","status":"RECRUITING","sponsor":"LEO Pharma","startDate":"2024-06-10","conditions":"Atopic Dermatitis","enrollment":195},{"nctId":"NCT05843669","phase":"PHASE4","title":"A Study to Explore if Long-term Use of Mucinex Can Help With Symptoms in Patients With Stable Chronic Bronchitis.","status":"COMPLETED","sponsor":"American Health Research","startDate":"2023-07-17","conditions":"Chronic Bronchitis","enrollment":82},{"nctId":"NCT07481058","phase":"PHASE2","title":"KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer","status":"RECRUITING","sponsor":"Beijing Konruns Pharmaceutical Co., Ltd.","startDate":"2025-12-12","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":60},{"nctId":"NCT05748171","phase":"PHASE2","title":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-05-17","conditions":"ACUTE LYMPHOBLASTIC LEUKEMIA","enrollment":100},{"nctId":"NCT07469293","phase":"PHASE3","title":"Efficacy and Safety of Intra-arterial Tenecteplase in Acute Ischemic Stroke Patients With Medium Vessel Occlusion Stroke (DATE-MeVO)","status":"NOT_YET_RECRUITING","sponsor":"Southwest Hospital, China","startDate":"2026-03-25","conditions":"Acute Ischemic Stroke","enrollment":488},{"nctId":"NCT07182227","phase":"PHASE1, PHASE2","title":"PS-002 for the Treatment of IgA Nephropathy in Adults","status":"RECRUITING","sponsor":"Purespring Therapeutics Limited","startDate":"2026-02","conditions":"Immunoglobulin A (IgA) Nephropathy","enrollment":32},{"nctId":"NCT07486713","phase":"PHASE4","title":"Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies","status":"RECRUITING","sponsor":"Rigel Pharmaceuticals","startDate":"2026-02-23","conditions":"AML (Acute Myeloid Leukemia), Glioma, Cholangiocarcinoma","enrollment":16},{"nctId":"NCT05681884","phase":"PHASE2","title":"Safety and Efficacy of Faricimab in Patients With NPDR","status":"COMPLETED","sponsor":"Greater Houston Retina Research","startDate":"2023-05-16","conditions":"Non-Proliferative Diabetic Retinopathy","enrollment":179},{"nctId":"NCT06057402","phase":"PHASE4","title":"Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-10-03","conditions":"Multiple Myeloma","enrollment":80},{"nctId":"NCT04732871","phase":"PHASE3","title":"Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2021-02-15","conditions":"Respiratory Syncytial Virus Infections","enrollment":1720},{"nctId":"NCT07161037","phase":"PHASE2","title":"Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-11-19","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":24},{"nctId":"NCT07023341","phase":"PHASE3","title":"A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2025-06-30","conditions":"Obstructive Hypertrophic Cardiomyopathy","enrollment":36},{"nctId":"NCT06224907","phase":"PHASE3","title":"Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioMarin Pharmaceutical","startDate":"2023-12-25","conditions":"Hemophilia A","enrollment":6},{"nctId":"NCT07483450","phase":"PHASE4","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-07-04","conditions":"Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis","enrollment":60},{"nctId":"NCT06857942","phase":"PHASE4","title":"A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-03-19","conditions":"Psoriasis, Overweight or Obesity","enrollment":200},{"nctId":"NCT02938520","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-27","conditions":"HIV Infections","enrollment":631},{"nctId":"NCT06593392","phase":"PHASE2","title":"Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus","status":"RECRUITING","sponsor":"Vifor Fresenius Medical Care Renal Pharma","startDate":"2026-04-09","conditions":"Pruritus, Chronic Kidney Diseases","enrollment":18},{"nctId":"NCT07350863","phase":"PHASE1","title":"U69-CART-Cells For R/R T-ALL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-06-25","conditions":"Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma","enrollment":12},{"nctId":"NCT02257736","phase":"PHASE3","title":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2014-11-26","conditions":"Prostatic Neoplasms","enrollment":982},{"nctId":"NCT07313761","phase":"PHASE1","title":"A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2025-12-15","conditions":"Overweight and Obesity","enrollment":349},{"nctId":"NCT06801834","phase":"PHASE3","title":"Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-04-04","conditions":"Extensive Stage Small Cell Lung Cancer (ES-SCLC)","enrollment":695},{"nctId":"NCT07165015","phase":"PHASE1","title":"A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-09-18","conditions":"Renal Impairment, Healthy, Renal Insufficiency","enrollment":32},{"nctId":"NCT04020016","phase":"PHASE1","title":"Study of Nalbuphine ER in Participants With Hepatic Impairment","status":"COMPLETED","sponsor":"Trevi Therapeutics","startDate":"2019-06-12","conditions":"Hepatic Impairment","enrollment":28},{"nctId":"NCT05714202","phase":"PHASE3","title":"A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-03-23","conditions":"Bladder Cancer","enrollment":1135},{"nctId":"NCT07483255","phase":"NA","title":"A Phase II Trial of Fetal Embolization for Vein of Galen Malformation","status":"NOT_YET_RECRUITING","sponsor":"Darren Orbach","startDate":"2026-05","conditions":"Vein of Galen Malformations","enrollment":20},{"nctId":"NCT07130773","phase":"NA","title":"Comparative Intra-procedural Evaluation of Farapulse and FARAWAVE Nav Catheters","status":"RECRUITING","sponsor":"Cardiocentro Ticino","startDate":"2025-11-10","conditions":"Atrial Fibrillation (AF), Atrial Fibrillation Ablation, Pulsed Field Ablation","enrollment":58},{"nctId":"NCT07269327","phase":"PHASE1","title":"An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2025-11-24","conditions":"Fertility","enrollment":24},{"nctId":"NCT07205822","phase":"PHASE3","title":"A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-10-30","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT07269301","phase":"PHASE1","title":"A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-12-29","conditions":"Hepatic Impairment, Healthy","enrollment":26},{"nctId":"NCT07315360","phase":"PHASE1","title":"A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function","status":"RECRUITING","sponsor":"Pfizer","startDate":"2026-01-28","conditions":"Renal Impairment, Healthy","enrollment":28},{"nctId":"NCT06606847","phase":"PHASE2","title":"A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-24","conditions":"Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT04678648","phase":"PHASE1","title":"A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies","status":"RECRUITING","sponsor":"RasCal Therapeutics, Inc.","startDate":"2021-03-03","conditions":"Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer","enrollment":134},{"nctId":"NCT06980480","phase":"PHASE3","title":"A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-01-14","conditions":"Multiple Myeloma, Secondary Immunodeficiency","enrollment":183},{"nctId":"NCT02649959","phase":"PHASE3","title":"An Open Label Study of CM-AT for the Treatment of Children With Autism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Curemark","startDate":"2015-10","conditions":"Autism","enrollment":405},{"nctId":"NCT07476183","phase":"PHASE1","title":"Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia","status":"NOT_YET_RECRUITING","sponsor":"Apriligen, Inc.","startDate":"2026-03","conditions":"RPS19 Deficient Diamond-Blackfan Anemia","enrollment":4},{"nctId":"NCT07477418","phase":"PHASE1, PHASE2","title":"PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)","status":"NOT_YET_RECRUITING","sponsor":"University of Vermont","startDate":"2026-12","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms","enrollment":10},{"nctId":"NCT05693935","phase":"PHASE3","title":"A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","startDate":"2023-01-24","conditions":"Schizophrenia","enrollment":675},{"nctId":"NCT07156565","phase":"PHASE1","title":"Actinium Therapy for Late-stage Aggressive Sarcomas","status":"RECRUITING","sponsor":"Ratio Therapeutics, Inc.","startDate":"2025-11-12","conditions":"Advanced Soft Tissue Sarcoma","enrollment":30},{"nctId":"NCT07478471","phase":"","title":"Observational Study of Raxibacumab in Sporadic Cases of Systemic Anthrax","status":"NOT_YET_RECRUITING","sponsor":"Emergent BioSolutions","startDate":"2027-05","conditions":"Infections, Bacterial","enrollment":10},{"nctId":"NCT05909527","phase":"PHASE1, PHASE2","title":"A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma","status":"WITHDRAWN","sponsor":"Guangzhou Bio-gene Technology Co., Ltd","startDate":"2023-05-01","conditions":"T-Cell Acute Lymphocytic Leukemia","enrollment":""},{"nctId":"NCT06211764","phase":"PHASE3","title":"A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-09","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":272},{"nctId":"NCT07422285","phase":"PHASE1","title":"Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose","status":"RECRUITING","sponsor":"Amgen","startDate":"2026-01-16","conditions":"Healthy Participants, Pharmacokinetics","enrollment":400},{"nctId":"NCT04133636","phase":"PHASE2","title":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-11-07","conditions":"Multiple Myeloma","enrollment":210},{"nctId":"NCT07476378","phase":"NA","title":"A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-03","conditions":"Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Follicular, Lymphoma, Mantle-Cell","enrollment":69},{"nctId":"NCT07143604","phase":"PHASE2","title":"A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-08-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":33},{"nctId":"NCT05487885","phase":"PHASE4","title":"Anhedonia, Development, and Emotions: Phenotyping and Therapeutics","status":"COMPLETED","sponsor":"Erika Forbes","startDate":"2022-07-22","conditions":"Depression, Anhedonia","enrollment":123},{"nctId":"NCT07287397","phase":"PHASE1, PHASE2","title":"Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS","status":"RECRUITING","sponsor":"Vector Y Therapeutics","startDate":"2025-12-19","conditions":"Amyotrophic Lateral Sclerosis","enrollment":12},{"nctId":"NCT07476729","phase":"PHASE3","title":"International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)","status":"NOT_YET_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2026-04-01","conditions":"B-Cell Acute Lymphoblastic Leukaemia","enrollment":750},{"nctId":"NCT07475949","phase":"PHASE3","title":"Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2026-04","conditions":"Acute Ischemic Stroke, Tenecteplase","enrollment":352},{"nctId":"NCT03600883","phase":"PHASE1, PHASE2","title":"A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2018-08-27","conditions":"KRAS p.G12C Mutant Advanced Solid Tumors","enrollment":713},{"nctId":"NCT05114746","phase":"PHASE2","title":"Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-01-25","conditions":"Prostate Cancer","enrollment":87},{"nctId":"NCT03861273","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2019-07-29","conditions":"Hemophilia B","enrollment":51},{"nctId":"NCT06607627","phase":"PHASE3","title":"PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-11-13","conditions":"Generalized Myasthenia Gravis, gMG","enrollment":12},{"nctId":"NCT04588922","phase":"PHASE1, PHASE2","title":"Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML","status":"RECRUITING","sponsor":"Sellas Life Sciences Group","startDate":"2021-05-10","conditions":"Hematologic Malignancies","enrollment":160},{"nctId":"NCT07224529","phase":"PHASE4","title":"Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-04-01","conditions":"Meibomian Gland Dysfunction (MGD)","enrollment":48},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT05820386","phase":"NA","title":"Skin-to-skin Contact During the Transfer From the Delivery Room to the Neonatal Intensive Care Unit: Impact on Very Preterm Infants and Their Parents","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Tours","startDate":"2023-05-03","conditions":"Skin to Skin, Premature Newborns","enrollment":118},{"nctId":"NCT02932410","phase":"PHASE3","title":"A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Actelion","startDate":"2017-10-24","conditions":"Pulmonary Arterial Hypertension","enrollment":165},{"nctId":"NCT06315322","phase":"PHASE3","title":"A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2024-07-10","conditions":"Childhood Absence Epilepsy, Juvenile Absence Epilepsy","enrollment":120},{"nctId":"NCT07469969","phase":"NA","title":"Transcutaneous Auricular Vagus Nerve Stimulation Combined With Tailor-Made Notched Music Training Therapy for Chronic Subjective Tinnitus","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2026-04-01","conditions":"Chronic Subjective Tinnitus","enrollment":386},{"nctId":"NCT03591510","phase":"PHASE2","title":"A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2019-03-13","conditions":"FLT3-mutated Acute Myeloid Leukemia","enrollment":22},{"nctId":"NCT07469072","phase":"PHASE2","title":"Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in the Intensive Care Unit (ICU)","status":"NOT_YET_RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2026-02-25","conditions":"Continuous Renal Replacement Therapy (CRRT)","enrollment":92},{"nctId":"NCT07344168","phase":"NA","title":"EndoArt® Implantation in Subjects With Chronic Corneal Edema - US Study","status":"NOT_YET_RECRUITING","sponsor":"Eye-yon Medical","startDate":"2026-05-01","conditions":"Corneal Edema","enrollment":123},{"nctId":"NCT07426380","phase":"PHASE1","title":"A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02-24","conditions":"Kidney Disease, Renal Insufficiency Chronic, Kidney Failure, Chronic","enrollment":28},{"nctId":"NCT07470879","phase":"PHASE2","title":"A Study of How the Medicine Called \"Etrasimod\" Works in Children With the Gut Disease Called Ulcerative Colitis","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-03-31","conditions":"Colitis, Ulcerative","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":70,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ADCTA-G"],"phase":"marketed","status":"active","brandName":"Single group, open-label","genericName":"Single group, open-label","companyName":"Daewoong Pharmaceutical Co. LTD.","companyId":"daewoong-pharmaceutical-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}